AbbVie Is a Dividend Growth Stock at a Bargain Price
AbbVie reported fourth-quarter results that topped expectations. Its valuation discount is no longer warranted.
Gilead Sciences: Still on the Path to Recovery
Gilead released a mixed fourth-quarter earnings report. Longer-term investors should stick with the stock.
Coca-Cola's Earnings: Outperforming Its Peers
Coca-Cola reported better-than-expected fourth quarter earnings. This is likely to be more the rule than the exception going forward.
Altria's Earnings: Bull Case Still Intact for This Dividend Growth Stock
Altria's shares fell on disappointing earnings. However, a closer look suggests that the stock remains attractive for long-term investors.
Wells Fargo: Not Ready to Throw in the Towel
The news seems to go from bad to worse for Wells Fargo. But with a new CEO on board, could we be on the verge of a new dawn for the stock?
IBM: Is Big Blue Set for Sustained Growth?
IBM released earnings that were better than expected. Although the results were mixed, investors should be taking a closer look at the stock.
3 Stocks to Buy in a Bear Market
A significant correction is an inevitability at some point, if history is any guide. Here are three stocks to buy if the opportunity arises.
Why Cisco Systems is Overdue for a Rebound
Macroeconomic factors have clouded Cisco's recent performance. With those clouds now parting, the stock deserves a second look.
Bottom-Fishing The Energy Sector With Chevron
The energy sector seems overdue for a rebound. Chevron may be the best way to play it.
Is Warren Buffett's Berkshire Hathaway Still a Good Bet?
Berkshire has lagged the market over the recent past. It's time for the shares to play catch up.
What Would Warren Buffett's Mentor Think About Accenture?
On many dimensions, Accenture qualifies as a great company. But is it a great investment?
Bristol Myers Squibb: A Cash-Generating Machine at a Cheap Price
This big pharma stock provides value in an increasingly expensive market.
Why AbbVie Is a Dividend Growth Stock That's Too Cheap to Ignore
The Allergan deal will cement AbbVie’s position as a diversified pharmaceutical company with sustainable growth. It’s time for the shares to play catchup.
Is IBM Ready for a Big Surge?
IBM is lagging behind its technology peers. But its acquisition of Red Hat earlier this year may be a game changer.
Wells Fargo: Time to Climb Aboard the Stagecoach
With a new CEO on board, Wells Fargo can start to put its problems behind it.
Is Altria Going Up in Smoke or Just Going Up?
Persistent bad news has driven the tobacco company to its lowest valuation in 10 years. It’s time to have a second look.
Is The Future Finally Looking Up For Gilead Sciences?
It’s been a rough ride for Gilead Sciences. But the biotech may soon be sailing through smoother seas.